Tumour Necrosis Factor (TNF) in Psoriatic Arthritis: Pathophysiology and Treatment with TNF Inhibitors

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2002 Mar 5

PMID 11874829

Citations 31

Authors

P J Mease

Affiliations

Soon will be listed here.

Abstract

High levels of proinflammatory cytokines, including tumour necrosis factor (TNF), have been detected in psoriatic skin lesions and joints of patients with the inflammatory disease. Early results of treatment of psoriatic arthritis and psoriasis with TNF neutralising agents are encouraging, but whether these agents will be able to improve long term outcomes, such as disability, is not yet known.

Citing Articles

Increased Circulating CD14+ Monocytes in Patients with Psoriatic Arthritis Presenting Impaired Apoptosis Activity.

Lin S, Hsu C, Li S Biomedicines. 2024; 12(4).

PMID: 38672131 PMC: 11048590. DOI: 10.3390/biomedicines12040775.

The Role of Bone Morphogenetic Protein Receptor Type 2 () and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling.

Devendran A, Kar S, Bailey R, Trivieri M Cells. 2022; 11(23).

PMID: 36497082 PMC: 9741276. DOI: 10.3390/cells11233823.

Small RNA Expression Profiling Reveals hsa-miR-181d-5p Downregulation Associated With TNF-α Overexpression in Sjögren's Syndrome Patients.

Castro I, Carvajal P, Jara D, Aguilera S, Heathcote B, Barrera M Front Immunol. 2022; 13:870094.

PMID: 35432384 PMC: 9010469. DOI: 10.3389/fimmu.2022.870094.

Missense variants in the TNFA epitopes and their effects on interaction with therapeutic antibodies-in silico analysis.

Ahsan T, Sajib A J Genet Eng Biotechnol. 2022; 20(1):7.

PMID: 35006391 PMC: 8748575. DOI: 10.1186/s43141-021-00288-y.

MiR-193b-3p-ERBB4 axis regulates psoriasis pathogenesis via modulating cellular proliferation and inflammatory-mediator production of keratinocytes.

Huang C, Zhong W, Ren X, Huang X, Li Z, Chen C Cell Death Dis. 2021; 12(11):963.

PMID: 34667159 PMC: 8526743. DOI: 10.1038/s41419-021-04230-5.

References

Fournie B, Crognier L, Arnaud C, Zabraniecki L, Marc V, Ginesty E . Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients. Rev Rhum Engl Ed. 1999; 66(10):446-56. View

Wolf R, Ruocco V . Triggered psoriasis. Adv Exp Med Biol. 1999; 455:221-5. DOI: 10.1007/978-1-4615-4857-7_32. View

Rahman P, Schentag C, Beaton M, Gladman D . Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis. Clin Exp Rheumatol. 2000; 18(1):7-12. View

Ortonne J . Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol. 2000; 140 Suppl 54:1-7. DOI: 10.1046/j.1365-2133.1999.140s54001.x. View

Shbeeb M, Uramoto K, Gibson L, OFallon W, Gabriel S . The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000; 27(5):1247-50. View

Van den Bosch F, Kruithof E, Baeten D, de Keyser F, Mielants H, Veys E . Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000; 59(6):428-33. PMC: 1753171. DOI: 10.1136/ard.59.6.428. View

Danning C, Illei G, Hitchon C, Greer M, Boumpas D, McInnes I . Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000; 43(6):1244-56. DOI: 10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2. View

Mease P, GOFFE B, Metz J, VanderStoep A, Finck B, Burge D . Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356(9227):385-90. DOI: 10.1016/S0140-6736(00)02530-7. View

Baseta J, Stutman O . TNF regulates thymocyte production by apoptosis and proliferation of the triple negative (CD3-CD4-CD8-) subset. J Immunol. 2000; 165(10):5621-30. DOI: 10.4049/jimmunol.165.10.5621. View

10.

Moll J, WRIGHT V . Psoriatic arthritis. Semin Arthritis Rheum. 1973; 3(1):55-78. DOI: 10.1016/0049-0172(73)90035-8. View

11.

FREDRIKSSON T, Pettersson U . Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978; 157(4):238-44. DOI: 10.1159/000250839. View

12.

Luzar M . Hydroxychloroquine in psoriatic arthropathy: exacerbations of psoriatic skin lesions. J Rheumatol. 1982; 9(3):462-4. View

13.

Willkens R, Williams H, WARD J, Egger M, Reading J, Clements P . Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984; 27(4):376-81. DOI: 10.1002/art.1780270403. View

14.

Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A . Psoriatic arthritis in psoriatic patients. Br J Rheumatol. 1984; 23(4):246-50. DOI: 10.1093/rheumatology/23.4.246. View

15.

Dayer J, Beutler B, Cerami A . Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985; 162(6):2163-8. PMC: 2187983. DOI: 10.1084/jem.162.6.2163. View

16.

Bertolini D, Nedwin G, Bringman T, Smith D, Mundy G . Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986; 319(6053):516-8. DOI: 10.1038/319516a0. View

17.

Saklatvala J . Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986; 322(6079):547-9. PMC: 7095107. DOI: 10.1038/322547a0. View

18.

Tracey K, Vlassara H, Cerami A . Cachectin/tumour necrosis factor. Lancet. 1989; 1(8647):1122-6. DOI: 10.1016/s0140-6736(89)92394-5. View

19.

McGonagle D, Conaghan P, Emery P . Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum. 1999; 42(6):1080-6. DOI: 10.1002/1529-0131(199906)42:6<1080::AID-ANR2>3.0.CO;2-7. View

20.

Marsal S, Martinez M, Gallardo D, Ribera A, LIENCE E . Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford). 1999; 38(4):332-7. DOI: 10.1093/rheumatology/38.4.332. View